227 related articles for article (PubMed ID: 27830999)
1. The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts.
Scherber RM; Geyer HL; Dueck AC; Kosiorek HE; Finazzi G; Cavazzina R; Masciulli A; Scarano M; Vannucchi AM; Mesa RA; Barbui T
Leuk Lymphoma; 2017 Jun; 58(6):1481-1487. PubMed ID: 27830999
[TBL] [Abstract][Full Text] [Related]
2. Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study.
Grunwald MR; Burke JM; Kuter DJ; Gerds AT; Stein B; Walshauser MA; Parasuraman S; Colucci P; Paranagama D; Savona MR; Mesa R
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):579-584.e1. PubMed ID: 31303457
[TBL] [Abstract][Full Text] [Related]
3. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
Geyer H; Scherber R; Kosiorek H; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Maldonado N; Barosi G; Ferrari ML; Gale RP; Birgegard G; Xu Z; Zhang Y; Sun X; Xu J; Zhang P; te Boekhorst PA; Commandeur S; Schouten H; Pahl HL; Griesshammer M; Stegelmann F; Lehmann T; Senyak Z; Vannucchi AM; Passamonti F; Samuelsson J; Mesa RA
J Clin Oncol; 2016 Jan; 34(2):151-9. PubMed ID: 26598745
[TBL] [Abstract][Full Text] [Related]
4. Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.
Mesa R; Verstovsek S; Kiladjian JJ; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Zhen H; Jones MM; Parasuraman S; Li J; Côté I; Habr D; Vannucchi AM
Eur J Haematol; 2016 Aug; 97(2):192-200. PubMed ID: 26608702
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany.
Jentsch-Ullrich K; Eberhardt J; Zeremski V; Koehler M; Wolleschak D; Heidel FH
J Cancer Res Clin Oncol; 2016 Sep; 142(9):2041-9. PubMed ID: 27431664
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera.
Crodel CC; Jentsch-Ullrich K; Reiser M; Jacobasch L; Sauer A; Tesch H; Ulshöfer T; Wunschel R; Palandri F; Heidel FH
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2693-2705. PubMed ID: 34807311
[TBL] [Abstract][Full Text] [Related]
7. [The relationship between symptom burden and hematologic responses after treatment with interferon/hydroxyurea in patients with polycythemia vera].
Liu D; Xu ZF; Qin TJ; Qu SQ; Sun XJ; Li B; Pan LJ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):635-641. PubMed ID: 34547868
[No Abstract] [Full Text] [Related]
8. Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States.
Grunwald MR; Stein BL; Boccia RV; Oh ST; Paranagama D; Parasuraman S; Colucci P; Mesa R
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):788-795.e2. PubMed ID: 30245100
[TBL] [Abstract][Full Text] [Related]
9. Hematocrit levels and thrombotic events in patients with polycythemia vera: an analysis of Veterans Health Administration data.
Parasuraman S; Yu J; Paranagama D; Shrestha S; Wang L; Baser O; Scherber R
Ann Hematol; 2019 Nov; 98(11):2533-2539. PubMed ID: 31552445
[TBL] [Abstract][Full Text] [Related]
10. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms.
Abelsson J; Andréasson B; Samuelsson J; Hultcrantz M; Ejerblad E; Johansson B; Emanuel R; Mesa R; Johansson P
Leuk Lymphoma; 2013 Oct; 54(10):2226-30. PubMed ID: 23398206
[TBL] [Abstract][Full Text] [Related]
11. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
12. The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis.
Evers D; Kerkhoffs JL; Van Egmond L; Schipperus MR; Wijermans PW
J Clin Apher; 2014 Jun; 29(3):133-8. PubMed ID: 24130064
[TBL] [Abstract][Full Text] [Related]
13. [The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients].
Xu J; Xu Z; Wang J; Li B; Sun X; Qin T; Zhang Y; Zhang H; Fang L; Pan L; Hu N; Qu S; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):26-9. PubMed ID: 26876249
[TBL] [Abstract][Full Text] [Related]
14. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
Kremyanskaya M; Kuykendall AT; Pemmaraju N; Ritchie EK; Gotlib J; Gerds A; Palmer J; Pettit K; Nath UK; Yacoub A; Molina A; Saks SR; Modi NB; Valone FH; Khanna S; Gupta S; Verstovsek S; Ginzburg YZ; Hoffman R;
N Engl J Med; 2024 Feb; 390(8):723-735. PubMed ID: 38381675
[TBL] [Abstract][Full Text] [Related]
15. The WHO diagnostic criteria for polycythemia vera-role of red cell mass versus hemoglobin/hematocrit level and morphology.
Jakovic L; Gotic M; Gisslinger H; Soldatovic I; Sefer D; Tirnanic M; Lekovic D; Jovanovic MP; Schalling M; Gisslinger B; Beham-Schmid C; Simonitsch-Klupp I; Thiele J
Ann Hematol; 2018 Sep; 97(9):1581-1590. PubMed ID: 29717365
[TBL] [Abstract][Full Text] [Related]
16. Polycythemia Vera.
Spivak JL
Curr Treat Options Oncol; 2018 Mar; 19(2):12. PubMed ID: 29516275
[TBL] [Abstract][Full Text] [Related]
17. Polycythemia vera: a review.
Golden C
Clin J Oncol Nurs; 2003; 7(5):553-6. PubMed ID: 14603552
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States.
Mesa R; Boccia RV; Grunwald MR; Oh ST; Colucci P; Paranagama D; Parasuraman S; Stein BL
Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):590-596. PubMed ID: 30122202
[TBL] [Abstract][Full Text] [Related]
19. Real-world treatments and thrombotic events in polycythemia vera patients in the USA.
Verstovsek S; Pemmaraju N; Reaven NL; Funk SE; Woody T; Valone F; Gupta S
Ann Hematol; 2023 Mar; 102(3):571-581. PubMed ID: 36637474
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic erythroapheresis: Experience in patients with polycythemia vera and secondary erythrocytosis.
Parra Salinas I; Recasens Flores V; Montañés MÁ; García-Erce JA
Med Clin (Barc); 2020 Jan; 154(1):16-19. PubMed ID: 30795904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
